Curis Inc., a biotechnology company specializing in the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, has announced upcoming milestones in its clinical research. The company is set to present additional data from the TakeAim Lymphoma study, specifically concerning R/R PCNSL patients, later this year. Furthermore, Curis is conducting an ongoing triplet study that evaluates different dosing regimens of emavusertib, venetoclax, and azacitidine in frontline acute myeloid leukemia $(AML.AU)$ patients. Data from this study is anticipated to be shared at the 67th American Society of Hematology $(ASH)$ Annual Meeting in December.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.